Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 21, Issue 9, 1998, Pages 873-878

  Aurlien, E ^a   Holte, H ^a   Pharo, A ^a   Kvaloy S ^a   Jakobsen, E ^a   Smeland, E B ^a   Kvalheim, G ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

CD34+ cells; Chemotherapy; Combination; G CSF malignant lymphoma; MIME; PBPC mobilization

Indexed keywords

CARMUSTINE; CD34 ANTIGEN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOGUAZONE;

ADOLESCENT; ADULT; ARTICLE; BEAM THERAPY; BONE MARROW TOXICITY; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKAPHERESIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031943737     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701192     Document Type: Article

References (24)

1. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim peripheral blood progenitor cell transplantation vs autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
2. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277-284.
3. Gratwohl A, Hermans J, Baldomero H et al. Indications for haemopoietic precursor cell transplants in Europe. European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996; 92: 35-43.
4. Pettengell R, Testa NG, Swindell R et al. Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma (see comments). Blood 1993; 82: 2239-2248.
5. To LB, Haylock D, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233-2258.
6. + hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 74: 1905-1914.
7. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 691-697.
8. To LB, Shepperd KM, Haylock DN et al. Single high-doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood (see comments). Exp Hematol 1990; 18: 442-447.
9. 2 in patients with advanced cancer. Aust NZ J Med 1992; 22: 660-664.
10. Cabanillas F, Hagemeister FB, McLaughlin P et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987; 5: 407-412.
11. Enblad G, Hagberg H, Glimelius B. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for non-Hodgkin's lymphomas: a Swedish national prospective study. Swedish Lymphoma Study Group. Acta Oncol 1996; 35: 165-170.
12. Siena S, Bregni M, Brando B et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400-409.
13. + cell enumeration in blood and leukapheresis products: report from the Second Nordic Workshop. J Hematother 1996; 5: 237-245.
14. Eaves CJ, Myelopoiesis. In: Henderson ES, Lister TA, Greaves MF (eds). Leukemia. Saunders: London, 1996, pp 46-63.
15. Dreger P, Marquardt P, Haferlach T et al. Effective mobilization of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product. Br J Cancer 1993; 68: 950-957.
16. Lien HH, Blomlie V, Blystad AK et al. Bone marrow MR imaging before and after autologous marrow transplantation in lymphoma patients without known bone marrow involvement. Acta Radiol 1997; 38: 896-902.
17. Watts MJ, Sullivan AM, Jamieson E et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997; 15: 535-546.
18. Baars JW, Holtkamp MJ, Nooyen WJ et al. Mobilization of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (filgrastim) in patients with malignant lymphomas or solid tumours. Anticancer Res 1996; 16: 3089-3095.
19. McQuaker G, Haynes AP, Stainer C et al. Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. Br J Haematol 1997; 98: 228-233.
20. Haas R, Mohle R, Fruhauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
21. Dreger P, Kloss M, Petersen B et al. Autologous progenitor cell transplantation: prior exposure to stem cell toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86: 3970-3978.
22. Schwartzberg LS, Birch R, Hazelton B et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1992; 1: 317-327.
23. Kvalheim G, Wang MY, Pharo A et al. Purging of tumor cells from leukapheresis products: experimental and clinical aspects. J Hematother 1996; 5: 427-436.
24. + cells from peripheral blood progenitor cell products. Bone Marrow Transplant 1996; 17 (Suppl. 1): 57.